# University Hospital Basel / Tumour Centre

Source: https://onco.cc/institutions/usb-basel/  
OnCo record `usb-basel` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

University Hospital Basel coordinates cancer care in the home city of Roche and Novartis; its groups run early-phase tumour immunology trials, study breast cancer metastasis, and develop peptide radioligands such as exendin-based imaging of insulinomas.

## Summary

The Tumour Centre of University Hospital Basel coordinates cancer care in a city that is also headquarters to Roche and Novartis and home to the Friedrich Miescher Institute and the University of Basel's Department of Biomedicine. Alfred Zippelius and Heinz Läubli lead tumour immunology and early-phase immunotherapy trials, Mohamed Bentires-Alj studies breast cancer metastasis, Viola Heinzelmann-Schwarz heads gynaecological oncology, and the nuclear medicine and radiopharmaceutical chemistry groups (Damian Wild, Melpomeni Fani) develop novel peptide radioligands, including exendin-based imaging of insulinomas. The hospital runs haematology and CAR-T, thoracic and visceral surgery, and radiotherapy, and hosts SAKK and pharma-sponsored trials.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: USB; Universitätsspital Basel; Tumorzentrum Basel
- City: Basel, CH
- Type: hospital
- Website: https://www.unispital-basel.ch/en/

## Sources

- Homepage: https://www.unispital-basel.ch/en/
- Tumorzentrum: https://www.unispital-basel.ch/en/tumorzentrum

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/), [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [PET/CT](https://onco.cc/technologies/pet-ct/), [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/)
- companies: [Novartis](https://onco.cc/companies/novartis/), [Roche / Genentech](https://onco.cc/companies/roche-genentech/)
- institutions: [Inselspital, Bern University Hospital / University Cancer Center Inselspital](https://onco.cc/institutions/inselspital-bern/), [University Hospital Zurich / Comprehensive Cancer Center Zurich](https://onco.cc/institutions/usz-zurich/)
- people: [Astrid Beiglböck](https://onco.cc/people/astrid-beiglbock/), [Benjamin Kasenda](https://onco.cc/people/benjamin-kasenda/), [Daniel Staub](https://onco.cc/people/daniel-staub/), [Rakesh Padiyath](https://onco.cc/people/rakesh-padiyath/)
- bottlenecks: [Metastasis is understood least and studied last](https://onco.cc/bottlenecks/b-metastasis-biology/)

---
JSON: https://onco.cc/api/v1/entities/usb-basel.json